Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

0(0%)

Results Posted

33%(2 trials)

Phase Distribution

Ph phase_2

38%

Ph phase_3

13%

Ph phase_4

38%

Ph phase_1

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

1(12.5%)

Phase 2Efficacy & side effects

3(37.5%)

Phase 3Large-scale testing

1(12.5%)

Phase 4Post-market surveillance

3(37.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Other(2)

Detailed Status

Completed6

unknown2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (12.5%)

Phase 23 (37.5%)

Phase 31 (12.5%)

Phase 43 (37.5%)

Trials by Status

completed675%

unknown225%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_2

Nadolol for Proliferating Infantile Hemangiomas

NCT01010308

completedphase_3

Nadolol Versus Propranolol in Children With Infantile Hemangiomas

NCT02505971

completedphase_2

Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

NCT01825122

unknownphase_2

Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma

NCT01804218

completedphase_1

Oral Nadolol for the Treatment of Adults With Mild Asthma

NCT00670267

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT01010308Phase 2

Nadolol for Proliferating Infantile Hemangiomas

Completed

NCT02505971Phase 3

Nadolol Versus Propranolol in Children With Infantile Hemangiomas

Completed

NCT01825122Phase 2

Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

Completed

NCT01804218Phase 2

Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma

Unknown

NCT00670267Phase 1

Oral Nadolol for the Treatment of Adults With Mild Asthma

Completed

NCT00567216Phase 4

Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding

Unknown

NCT00921349Phase 4

A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis

Completed

NCT00450164Phase 4

Secondary Prophylaxis After Variceal Bleeding in Non-Responders

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8